Search

Your search keyword '"Liao, Lin"' showing total 43 results
Start Over Author "Liao, Lin" Publisher wiley
43 results on '"Liao, Lin"'

3. Efficacy and safety of janagliflozin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial

Author

Gao, Leili, primary, Cheng, Zhifeng, additional, Su, Benli, additional, Su, Xiuhai, additional, Song, Weihong, additional, Guo, Yushan, additional, Liao, Lin, additional, Chen, Xiaowen, additional, Li, Jiarui, additional, Tan, Xingrong, additional, Xu, Fangjiang, additional, Pang, Shuguang, additional, Wang, Kun, additional, Ye, Jun, additional, Wang, Yuan, additional, Chen, Lili, additional, Sun, Jingfang, additional, and Ji, Linong, additional

Published
2022
Full Text
View/download PDF

12. Lin28a up‐regulation is associated with the formation of restenosis via promoting proliferation and migration of vascular smooth muscle cells

Author

Zou, Zhiwei, primary, Zhou, Xiaojun, additional, Zhang, Ruzhen, additional, Zhang, Qian, additional, Jiang, Shan, additional, Xu, Chunmei, additional, Zhang, Rui, additional, Xie, Tianyue, additional, Zhu, Huangao, additional, Gong, Piyun, additional, Zhang, Dongmei, additional, Ma, Huimei, additional, Liao, Lin, additional, and Dong, Jianjun, additional

Published
2020
Full Text
View/download PDF

14. Integrated analysis identifies DUSP5 as a novel prognostic indicator for thyroid follicular carcinoma

Author

Zhang, Qian, primary, Xing, Yiqian, additional, Jiang, Shan, additional, Xu, Chunmei, additional, Zhou, Xiaojun, additional, Zhang, Rui, additional, Xie, Tianyue, additional, Zou, Zhiwei, additional, Gong, Piyun, additional, Zhu, Huangao, additional, Zhang, Dongmei, additional, Ma, Huimei, additional, Liao, Lin, additional, and Dong, Jianjun, additional

Published
2019
Full Text
View/download PDF

17. Plasma levels of von Willebrand factor in type 2 diabetes patients with and without cardiovascular diseases: A meta‐analysis

Author

Liao Lin, Ju Liu, Xun Peng, Xia Wang, Mengge Fan, and Junyu Zhao

Subjects
medicine.medical_specialty, endocrine system diseases, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Gastroenterology, Pathogenesis, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Von Willebrand factor, Risk Factors, Diabetes mellitus, Internal medicine, von Willebrand Factor, Internal Medicine, medicine, Humans, biology, business.industry, nutritional and metabolic diseases, Type 2 Diabetes Mellitus, Plasma levels, Prognosis, medicine.disease, Confidence interval, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Meta-analysis, biology.protein, business, Biomarkers
Abstract

Chronic vascular complications are the major causes of death and disability of type 2 diabetes mellitus (T2DM) patients. von Willebrand factor (vWF) is involved in pathogenesis of cardiovascular diseases (CVD). Previous studies showed elevated plasma levels of vWF in T2DM patients with CVD, but the association has not been validated. The aim of this meta-analysis was to compare plasma levels of vWF in T2DM patients with and without CVD. We performed a meta-analysis based on published case-control studies of vWF in T2DM patients with and without CVD indexed in PubMed and other databases updated to April 2018. After independently assessing methodological quality and extracting data, 9 eligible studies were obtained including 576 cases and 632 controls. The standard mean difference (SMD) and 95% confidence intervals (95% CI) were calculated using random-effects model. Meta-analysis showed that plasma level of vWF was significantly higher in T2DM patients with CVD than T2DM patients without CVD (SMD = 0.61; 95% CI, 0.32-0.90; P

Published
2019

29. Vascularization of Porous PolyHEMA Scaffolds

Author

Liao, Lin, primary, Cho, Eugenia, additional, Boico, Alina, additional, Register, Janna, additional, Fales, Andrew, additional, Helton, Kristen, additional, Wisniewski, Natalie, additional, Vo‐Dinh, Tuan, additional, Palmer, Gregory, additional, and Klitzman, Bruce, additional

Published
2015
Full Text
View/download PDF

41. Hypoglycaemic effects of glimepiride in sulfonylurea receptor 1 deficient rat.

Author

Zhou X, Zhang R, Zou Z, Shen X, Xie T, Xu C, Dong J, and Liao L

Subjects
Animals, Blood Glucose drug effects, Diabetes Mellitus, Experimental metabolism, Diabetes Mellitus, Experimental pathology, Hypoglycemic Agents administration & dosage, Rats, Sulfonylurea Compounds administration & dosage, Sulfonylurea Receptors metabolism, Diabetes Mellitus, Experimental drug therapy, Hypoglycemic Agents pharmacology, Sulfonylurea Compounds pharmacology, Sulfonylurea Receptors antagonists & inhibitors, Sulfonylurea Receptors deficiency
Abstract

Background and Purpose: Sulfonylureas (SUs) have been suggested to have an insulin-independent blood glucose-decreasing activity due to an extrapancreatic effect. However, a lack of adequate in vivo evidence makes this statement controversial. Here, we aimed to evaluate whether glimepiride has extrapancreatic blood glucose-lowering activity in vivo., Experimental Approach: Sulfonylurea receptor 1 deficient (SUR1 -/- ) rats were created by means of transcription activator-like effector nucleases (TALEN)-mediated gene targeting technology. Type 2 diabetic models were established by feeding a high-fat diet and administering a low-dose of streptozotocin. These rats were then randomly divided into four groups: glimepiride, gliclazide, metformin and saline. All rats were treated for 2 weeks., Key Results: Glimepiride decreased blood glucose levels and increased insulin sensitivity without elevating insulin levels. Gliclazide showed similar effects as glimepiride. Both agents were weaker than metformin. Further mechanistic investigations revealed that glimepiride increased hepatic glycogen synthesis and decreased gluconeogenesis, which were accompanied by the activation of Akt in the liver. Moreover, glimepiride increased both total and membrane glucose transporter 4 (GLUT4) levels in muscle and fat, which might be attributed to insulin receptor-independent IRS1/Akt activation., Conclusion and Implications: Glimepiride possesses an extrapancreatic blood glucose-lowering effect in vivo, which might be attributed to its direct effect on insulin-sensitive tissues. Therefore, the combination of glimepiride with multiple insulin injections should not be excluded per se., (© 2018 The British Pharmacological Society.)

Published
2019
Full Text
View/download PDF

42. Combined use of Clauss and prothrombin time-derived methods for determining fibrinogen concentrations: Screening for congenital dysfibrinogenemia.

Author

Xiang L, Luo M, Yan J, Liao L, Zhou W, Deng X, Deng D, Cheng P, and Lin F

Subjects
Adolescent, Adult, Afibrinogenemia blood, Aged, Aged, 80 and over, Case-Control Studies, Child, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Sensitivity and Specificity, Young Adult, Afibrinogenemia diagnosis, Blood Coagulation Tests methods, Fibrinogen analysis
Abstract

Background: In this study, the significance of fibrinogen concentration assessed by a combination of Clauss and prothrombin time (PT)-derived methods for screening for congenital dysfibrinogenemia were investigated, and the screening efficiency of fibrinogen PT-derived/Clauss ratio on congenital dysfibrinogenemia was analyzed., Methods: We compared fibrinogen concentrations determined by the Clauss, PT-derived, and enzyme-linked immunosorbent assay (ELISA) methods in 73 patients with congenital dysfibrinogenemia and 81 normal controls. Receiver operating characteristic (ROC) curves were utilized to evaluate the efficacy of fibrinogen PT-derived/Clauss ratio in screening for congenital dysfibrinogenemia., Results: Fibrinogen concentrations determined by the Clauss method were dramatically lower than by the PT-derived method and ELISA, and correlated poorly with the latter two methods in patients with congenital dysfibrinogenemia. Fibrinogen concentrations in normal controls were slightly lower according to the Clauss method than to the PT-derived method and ELISA; however, each method yielded results within the normal range and the correlation was good. The area under the ROC curve of fibrinogen PT-derived/Clauss ratio for diagnosis of congenital dysfibrinogenemia was 1 with a standard error of 0, 95% confidence interval of 0.976-1.00, and optimal critical diagnosis point of 1.43. When fibrinogen PT-derived/Clauss ratio was >1.43, the sensitivity and specificity for diagnosis of congenital dysfibrinogenemia were both 100%., Conclusions: The combined use of Clauss and PT-derived methods for determining fibrinogen concentrations improves the efficiency of screening for congenital dysfibrinogenemia, as the fibrinogen PT-derived/Clauss ratio has high sensitivity and specificity in diagnosis of congenital dysfibrinogenemia. This ratio could serve an important screening tool for this disease., (© 2017 Wiley Periodicals, Inc.)

Published
2018
Full Text
View/download PDF

43. Management of dysfibrinogenemia in pregnancy: A case report.

Author

Yan J, Deng D, Cheng P, Liao L, Luo M, and Lin F

Subjects
Blood Coagulation Tests, DNA Mutational Analysis, Female, Fibrinogen analysis, Fibrinogen genetics, Humans, Pregnancy, Afibrinogenemia diagnosis, Afibrinogenemia genetics, Afibrinogenemia therapy, Pregnancy Complications, Hematologic diagnosis, Pregnancy Complications, Hematologic genetics, Pregnancy Complications, Hematologic therapy
Abstract

Background: Dysfibrinogenemia is a rare coagulation disorder caused by mutations in the fibrinogen gene that results in abnormal fibrinogen function. Dysfibrinogenemia has a wide spectrum of clinical manifestations including asymptomatic(55%), hemorrhage (25%), and thrombosis (20%)., Methods: We reported a 30-year-old woman with 35 weeks gestation. She was misdiagnosed with hypofibrinogenemia in a local hospital, and then she was treated with fibrinogen concentrate. However, she was diagnosed as dysfibrinogenemia in our hospital base on her low function fibrinogen level (0.55 g/L) and her normal immunologic fibrinogen level (3.80 g/L). This patient had neither bleeding symptom nor thromboembolic event. Her obstetrical history included one normal pregnancy in 2008 with uneventful full-term delivery., Results: Multidisciplinary experts suggested that there should be no specific intervention in this case because of the patient had no previous episodes of abnormal bleeding or thrombotic. She had an uneventful delivery with no abnormal bleeding symptom or thromboembolic., Conclusion: Dysfibrinogenemia patients without personal or family history of bleeding and thromboembolic events, do not need specific therapeutic intervention., (© 2017 Wiley Periodicals, Inc.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results